Skip NavigationSkip to Content
Evidence Needed to Support the Clinical Utility of Molecular Diagnostics
January 10-11, 2013
Top Right Header
Spacer image Spacer
Spacer Evidence Needed to Support the Clinical Utility of Molecular Diagnostics - Agenda

Agenda

Thursday, January 10, 2013

8:00 - 8:10 Welcome and charge to group Larry Norton
  
8:10 - 8:45 Keynote Steven Gutman
Long Day's Journey into Night: Molecular Diagnostics and the Quest for Clinical Utility
  
8:45 - 9:05 Special report Daniel Hayes
Generation of an OMICs-based Tumor Biomarker Test: the Institute of Medicine Recommendations for a Pathway Forward
 
9:05 - 10:00 Panel discussion Moderator: Richard Schilsky
 
Walter H. Koch (Roche)
An industry perspective on the development of companion diagnostics

James M. Rae (University of Michigan, Ann Arbor)
Development of a pharmacogenetic predictor

Steven Shak (Genome Health)
Translating omics predictors to different diseases - tailoring technology to the purpose
 
10:00 - 10:20 BREAK
 
10:20 - 10:30 Charge for breakout session 1
Define clinical utility in each context, and evidence needed to establish it.
 
10:30 - 1:00 Breakout session 1
 
PREDICTIVE ASSAYS
Group A Targeted agents, trial design, intended use
Leaders: Stanley Hamilton, William Barlow, David Carbone
Conference Room A

Group B Targeted agents, trial design, intended use
Leaders: Michael Birrer, Lisa McShane, Mickey Williams
Conference Room B
 
DISEASE CLASSIFIERS
Group A Intrinsic breast cancer subtypes
Leaders: Matthew Ellis, David Ransohoff, Sheila Taube
Conference Room C1

Group B Ovarian, NSCLC and colorectal gene expression profiles
Leaders: Fred Waldman, Mei Polley, Magdalena Thurin
Conference Room C2
 
MONITORING DISEASE RESPONSE/RECURRENCE
Group A Solid tumors, including functional imaging
Leaders: Tracy Lively, Daniel Sullivan, Gene Pennello
Conference Room G1

Group B Leukemia and lymphoma
Leaders: Jerald Radich, Kouros Owzar, Stephen Hunger
Conference Room G2
 
1:00 - 2:20 LUNCH
 
2:20 - 2:30 Charge for breakout session 2
Discuss strategies for collecting the evidence described in session 1.
 
2:30 - 5:00 Breakout session 2

Meet with the same groups in the same rooms as in the morning.
 
5:00 - 7:00 Breakout chairs prepare presentations for the morning session
 

Friday, January 11, 2013
 
8:00 - 8:15 Announcements and logistics
 
8:15 - 8:45 Report of assays to guide treatment Michael Birrer
 
8:45 - 9:15 Discussion
 
9:15 - 9:30 BREAK
 
9:30 - 10:00 Keynote James Doroshow
Opportunities and Challenges for NCI in Translating Novel Discoveries to Useful Clinical Tests
 
10:05 - 10:35 Report of assays to classify tumors Fred Waldman
 
10:35 - 10:50 Discussion
 
10:50 - 11:20 Report of assays for monitoring disease status Jerald Radich
 
11:20 - 11:45 Discussion
 
11:45 - noon Next steps: Janet Dancey, Barbara Conley
 
Noon ADJOURN

General Information

For conference related questions please contact Julia Lam
301-228-4141

Location


Natcher Auditorium
Building 45
NIH-Bethesda

Spacer Image
Bottom Conference Border